RCS - Verici Dx PLC - Clarava™ poster to be presented at ASN Kidney Week

Verici DxAnnouncement

02/11/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231102:nRSB1141Sa&default-theme=true

RNS Number : 1141S  Verici Dx PLC  02 November 2023

Verici Dx plc

("Verici Dx" or the "Company")

 

Clarava™ poster to be presented at ASN Kidney Week

 

International clinical validation study data to be presented at the largest
global gathering of kidney health professionals

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that it will present a poster on the successful
international clinical validation study for Clarava™, the Company's
pre-transplant blood-based prognostic test for the risk of early acute kidney
transplant rejection, at the American Society of Nephrology's annual
conference, ASN Kidney Week, being held from 2-5 November 2023 in
Philadelphia, PA.

 

The poster, titled "Multi-Center International Study to Validate a
Pre-Transplant Blood-Based Next-Generation Sequencing (NGS) Signature
Predicting Risk of Acute Rejection After Kidney Transplant", will be presented
from 10am-12pm on 2 November, in the Exhibit Hall at location TH-PO115.

 

The poster will describe the design and positive results of Clarava's™
successful validation study, as previously announced, and is expected to help
establish the product within the international nephrology community ahead of
commercial launch.

 

Clarava™ is the only pre-transplant test of its kind currently available
that can risk stratify patients based on their likely immune response to a
transplanted organ. This allows clinicians to identify patients most likely to
require increased monitoring, including increasing or decreasing adjustments
in the type, dose, and duration of immunosuppressive agents. Existing
approaches to assess rejection risk are standardised and typically based on
the recipient's race, age, previous transplant history and whether they have
antibodies against common donor antigens. As previously reported, the
Clarava™ personalised risk assessment is especially important for the
expanding Deceased Donor transplant population.

 

Sara Barrington, CEO of Verici Dx, said: "ASN Kidney Week is an important
platform for Verici Dx to raise awareness of its products including
Clarava(TM), being the largest international gathering attended by kidney
health professionals and featuring the latest advances in treatment, research
and cutting edge technology in the field of nephrology."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Sam Butcher / Jalini Kalaravy

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

 

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes.  The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFSFESFEDSESF